Generate Biomedicines (GENB)
Builds protein therapeutics through a closed-loop generative-biology platform.
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares.
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass.
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen.
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful intersection between health and AI.
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio.
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market
One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as February comes to a close. One large IPO is currently scheduled in the week ahead, although some smaller issuers may join the calendar throughout the week. Street research is expected for seven companies in the week ahead, and one lock-up period will be expiring.
Drug developer Generate Biomedicines raises $400 million in US IPO
Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share.
Generate Biomedicines aims to raise $425 million in US IPO
Drug developer Generate Biomedicines said on Monday it was aiming to raise as much as $425 million in its initial public offering in the United States.
Generate Biomedicines Begins IPO Push With Major Collaboration Deals
Generate Biomedicines is pursuing an IPO to fund its clinical trials and pipeline expansion efforts. GENB's lead asset, GB-0895, targets severe asthma and COPD, with Phase 3 enrollment expected to be completed by H2 2027. Strategic collaborations with Amgen and Novartis offer up to $2.9 billion in milestone potential, enhancing upside.